{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:57:06Z","timestamp":1788465426444,"version":"build-2803163510"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Intradialytic hypotension (IDH) is a significant complication in haemodialysis (HD) patients, affecting cardiovascular stability and treatment outcomes. Antihypertensive medications, while crucial for blood pressure control, can exacerbate IDH, necessitating careful drug selection and management. This review highlights the differential effects at the HD population level of drug classes such as beta and alpha-beta blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II antagonists, diuretics and calcium antagonists. Beta and alpha-beta blockers are linked to a higher risk of IDH due to their impact on heart rate and myocardial contractility, which can impair cardiovascular reflexes during dialysis. ACEIs and angiotensin II antagonists may increase the risk of hypotension by reducing vascular resistance. Diuretics can worsen volume depletion, especially when combined with ultrafiltration. Conversely, calcium antagonists have been associated with a lower risk of IDH in low-power clinical studies. Target trials represent an opportunity to generate high-quality evidence in the absence of randomized controlled trial (RCT) data. To fill the knowledge gap, this review discusses a target trial emulation study by Zoccali et al. that provides insights into the comparative risks of antihypertensive drugs using observational data. This study underscores the need for individualized treatment plans and highlights the importance of further research, particularly RCTs, to validate findings and explore long-term cardiovascular outcomes. This review aims to guide clinicians in optimizing antihypertensive therapy for HD patients, balancing effective blood pressure control with minimizing IDH risk.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf315","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:56:31Z","timestamp":1760097391000},"page":"ii47-ii54","source":"Crossref","is-referenced-by-count":3,"title":["Choosing the right antihypertensive drug to avoid intradialytic hypotension"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1996","authenticated-orcid":false,"given":"Carmine","family":"Zoccali","sequence":"first","affiliation":[{"name":"Renal Research Institute , New York, NY ,","place":["USA"]},{"name":"Institute of Molecular Biology and Genetics (Biogem) , Ariano Irpino ,","place":["Italy"]},{"name":"Associazione Ipertensione Nefrologia Trapianto Renale (IPNET), c\/o Nefrologia, Grande Ospedale Metropolitano , Reggio Calabria ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[{"name":"CNR-IFC, Institute of Clinical Physiology, Research Unit of Clinical Epidemiology , Reggio Calabria ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mallamaci","sequence":"additional","affiliation":[{"name":"Associazione Ipertensione Nefrologia Trapianto Renale (IPNET), c\/o Nefrologia, Grande Ospedale Metropolitano , Reggio Calabria ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len S","family":"Usvyat","sequence":"additional","affiliation":[{"name":"Renal Research Institute , New York, NY ,","place":["USA"]},{"name":"Fresenius Medical Care, Global Medical Office , Waltham, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin W","family":"Maddux","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care, Global Medical Office , Waltham, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Stuard","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care, Global Medical Office , Palazzo Pignano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2025121209163926800_bib1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12882-023-03263-6","article-title":"Impact of frequent intradialytic hypotension on quality of life in patients undergoing hemodialysis","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Nephrol"},{"key":"2025121209163926800_bib2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1681\/ASN.2014020222","article-title":"Association of mortality risk with various definitions of intradialytic hypotension","volume":"26","author":"Flythe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163926800_bib3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ekir.2022.10.031","article-title":"Why is intradialytic hypotension the commonest complication of outpatient dialysis treatments?","volume":"8","author":"Davenport","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025121209163926800_bib4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/ckj\/sfaa078","article-title":"An update review of intradialytic hypotension: concept, risk factors, clinical implications and management","volume":"13","author":"Kanbay","year":"2020","journal-title":"Clin Kidney J"},{"key":"2025121209163926800_bib5","doi-asserted-by":"crossref","first-page":"11532","DOI":"10.1038\/s41598-025-96286-y","article-title":"The relationship between intradialytic hypotension and health-related quality of life in patients undergoing hemodialysis: a cross-sectional study","volume":"15","author":"Zhi","year":"2025","journal-title":"Sci Rep"},{"key":"2025121209163926800_bib6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1681\/ASN.2010101119","article-title":"Intradialytic hypotension and vascular access thrombosis","volume":"22","author":"Chang","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163926800_bib7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2215\/CJN.03900808","article-title":"Hemodialysis-induced cardiac injury: determinants and associated outcomes","volume":"4","author":"Burton","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025121209163926800_bib8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-024-03856-9","article-title":"Modern tools for optimizing fluid management in dialysis patients: a comprehensive review","volume":"25","author":"Patel","year":"2024","journal-title":"BMC Nephrol"},{"key":"2025121209163926800_bib9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/sdi.12633","article-title":"Impact of drugs on intradialytic hypotension: antihypertensives and vasoconstrictors","volume":"30","author":"Chang","year":"2017","journal-title":"Semin Dial"},{"key":"2025121209163926800_bib10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/hdi.2000.4.1.8","article-title":"Continuous blood volume monitoring and ultrafiltration control","volume":"4","author":"Lopot","year":"2000","journal-title":"Hemodial Int"},{"key":"2025121209163926800_bib11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1046\/j.1523-1755.2002.00638.x","article-title":"Incident acute coronary syndromes in chronic dialysis patients in the United States","volume":"62","author":"Trespalacios","year":"2002","journal-title":"Kidney Int"},{"key":"2025121209163926800_bib12","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1046\/j.1523-1755.2002.00355.x","article-title":"Calcium channel blocker use and mortality among patients with end-stage renal disease","volume":"61","author":"Kestenbaum","year":"2002","journal-title":"Kidney Int"},{"key":"2025121209163926800_bib13","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1523-1755.2004.00473.x","article-title":"Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect?","volume":"65","author":"Ishani","year":"2004","journal-title":"Kidney Int"},{"key":"2025121209163926800_bib14","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1053\/j.ajkd.2003.08.028","article-title":"Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients","volume":"42","author":"Griffith","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2025121209163926800_bib15","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1001\/archinte.164.22.2465","article-title":"\u03b2-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality","volume":"164","author":"Abbott","year":"2004","journal-title":"Arch Intern Med"},{"key":"2025121209163926800_bib16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/ndt\/gfr460","article-title":"Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada","volume":"27","author":"Kitchlu","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163926800_bib17","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1093\/ndt\/gfp212","article-title":"Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS","volume":"24","author":"Lopes","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163926800_bib18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/sj.ki.5002745","article-title":"Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension","volume":"73","author":"Davenport","year":"2008","journal-title":"Kidney Int"},{"key":"2025121209163926800_bib19","author":"Renal Association Standards Committee","year":"2002","journal-title":"Treatment of adults and children with renal failure\u202f: standards and audit measures"},{"key":"2025121209163926800_bib20","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","article-title":"Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients","volume":"23","author":"Tepel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163926800_bib21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1542-4758.2009.00365.x","article-title":"Myocardial contractile function and intradialytic hypotension","volume":"13","author":"Owen","year":"2009","journal-title":"Hemodial Int"},{"key":"2025121209163926800_bib22","doi-asserted-by":"publisher","first-page":"c137","DOI":"10.1159\/000092910","article-title":"Can predialysis hypertension prevent intradialytic hypotension in hemodialysis patients?","volume":"103","author":"Takeda","year":"2006","journal-title":"Nephron Clin Pract"},{"issue":"Suppl 3","key":"2025121209163926800_bib23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.ajkd.2005.01.019","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2025121209163926800_bib24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/hdi.12138","article-title":"Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome","volume":"18","author":"Sands","year":"2014","journal-title":"Hemodial Int"},{"key":"2025121209163926800_bib25","doi-asserted-by":"publisher","first-page":"ii22","DOI":"10.1093\/ndt\/gfm019","article-title":"EBPG guideline on haemodynamic instability","volume":"22","author":"Kooman","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163926800_bib26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.pcad.2006.03.002","article-title":"Baroreflex function in hypertension: consequences for antihypertensive therapy","volume":"48","author":"Grassi","year":"2006","journal-title":"Prog Cardiovasc Dis"},{"key":"2025121209163926800_bib27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.kint.2020.01.046","article-title":"Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Flythe","year":"2020","journal-title":"Kidney Int"},{"key":"2025121209163926800_bib28","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.ekir.2020.08.031","article-title":"Dialysis-induced cardiovascular and multiorgan morbidity","volume":"5","author":"Canaud","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2025121209163926800_bib29","first-page":"V2-V33\u2013V2-V37","volume":"2","author":"Farzam","year":"2023","journal-title":"Encyclopedia of Toxicology, Fourth Edition: Volume 1\u20139"},{"key":"2025121209163926800_bib30","first-page":"V2-V427\u2013V2-V431","article-title":"Calcium channel blockers","volume":"2","author":"McKeever","year":"2024","journal-title":"Encyclopedia of Toxicology, Fourth Edition: Volume 1\u20139"},{"key":"2025121209163926800_bib31","first-page":"CD009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121209163926800_bib32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12882-017-0605-7","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials","volume":"18","author":"Liu","year":"2017","journal-title":"BMC Nephrol"},{"key":"2025121209163926800_bib33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1524-6175.2004.02866.x","article-title":"Angiotensin-converting enzyme inhibitors side effects\u2014physiologic and non-physiologic considerations","volume":"6","author":"Sica","year":"2004","journal-title":"J Clin Hypertens"},{"key":"2025121209163926800_bib34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/sdi.12483","article-title":"Are Diuretics underutilized in dialysis patients?","volume":"29","author":"Trinh","year":"2016","journal-title":"Semin Dial"},{"key":"2025121209163926800_bib35","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/0735-1097(96)00161-1","article-title":"Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion","volume":"28","author":"Dormans","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2025121209163926800_bib36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ndt\/gfw433","article-title":"Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association\u2013European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)","volume":"32","author":"Sarafidis","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163926800_bib37","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.2215\/CJN.00870116","article-title":"Pharmacotherapy of hypertension in chronic dialysis patients","volume":"11","author":"Georgianos","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025121209163926800_bib38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/ki.2009.469","article-title":"Blood pressure in chronic kidney disease stage 5D\u2014report from a Kidney Disease: Improving Global Outcomes controversies conference","volume":"77","author":"Levin","year":"2010","journal-title":"Kidney Int"},{"key":"2025121209163926800_bib39","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2025121209163926800_bib40","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163926800_bib41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/IJNRD.S414774","article-title":"Current knowledge of beta-blockers in chronic hemodialysis patients","volume":"16","author":"Haddiya","year":"2023","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2025121209163926800_bib42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/00041552-200303000-00001","article-title":"Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations","volume":"12","author":"Sica","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025121209163926800_bib43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet"},{"key":"2025121209163926800_bib44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis","volume":"406","author":"Rossignol","year":"2025","journal-title":"Lancet"},{"key":"2025121209163926800_bib45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2017.12.018","article-title":"Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data","volume":"96","author":"Speich","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2025121209163926800_bib46","article-title":"Causal inference: what if?","author":"Hern\u00e1n","year":"2023"},{"key":"2025121209163926800_bib47","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-159-8-201310150-00709","article-title":"Randomized trials analyzed as observational studies","volume":"159","author":"Hern\u00e1n","year":"2013","journal-title":"Ann Intern Med"},{"key":"2025121209163926800_bib48","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163926800_bib49","doi-asserted-by":"crossref","first-page":"e066306","DOI":"10.1136\/bmj-2021-066306","article-title":"Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study","volume":"375","author":"Fu","year":"2021","journal-title":"BMJ"},{"key":"2025121209163926800_bib50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa1000552","article-title":"A randomized, controlled trial of early versus late initiation of dialysis","volume":"363","author":"Cooper","year":"2010","journal-title":"N Engl J Med"},{"key":"2025121209163926800_bib51","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/EDE.0000000000001649","article-title":"Comparative Effectiveness of dynamic treatment strategies for medication use and dosage: emulating a target trial using observational data","volume":"34","author":"Birnie","year":"2023","journal-title":"Epidemiology"},{"key":"2025121209163926800_bib52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.kint.2019.01.017","article-title":"Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"96","author":"Chan","year":"2019","journal-title":"Kidney Int"},{"issue":"Suppl 4","key":"2025121209163926800_bib53","first-page":"S94","article-title":"EuCliD (European Clinical Database): a database comparing different realities","volume":"14","author":"Marcelli","year":"2001","journal-title":"J Nephrol"},{"key":"2025121209163926800_bib54","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2215\/CJN.0000000000000521","article-title":"Antihypertensive drug treatment and the risk for intra-hemodialysis hypotension","volume":"19","author":"Zoccali","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025121209163926800_bib55","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000504079","article-title":"Using bioimpedance spectroscopy to assess volume status in dialysis patients","volume":"49","author":"van der Sande","year":"2019","journal-title":"Blood Purif"},{"key":"2025121209163926800_bib56","first-page":"518","article-title":"The use of lung-ultrasound monitoring and the risk of intradialysis hypotension in hemodialysis patients: an analysis in the context of a randomized clinical trial","volume":"16","author":"Torino","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf315\/64660477\/sfaf315.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_2\/ii47\/64660477\/sfaf315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_2\/ii47\/64660477\/sfaf315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:16:45Z","timestamp":1765549005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/18\/Supplement_2\/ii47\/8284993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":56,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2025,12,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf315","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,13]]}}}